Comparative Pharmacology
Head-to-head clinical analysis: ANSPOR versus CEFTRIAXONE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ANSPOR versus CEFTRIAXONE.
ANSPOR vs CEFTRIAXONE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cephalexin is a first-generation cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), leading to cell lysis and death.
Ceftriaxone is a third-generation cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), leading to cell lysis and death. It has broad-spectrum activity against gram-positive and gram-negative bacteria.
250-500 mg orally every 6 hours for 10-14 days; maximum 4 g/day.
1-2 g IV/IM every 24 hours; maximum 4 g/day.
None Documented
None Documented
1.5–2 hours in adults with normal renal function; prolonged to 20–30 hours in severe renal impairment (CrCl <10 mL/min)
Clinical Note
moderateCeftriaxone + Probenecid
"The serum concentration of Probenecid can be increased when it is combined with Ceftriaxone."
Clinical Note
moderateCeftriaxone + Picosulfuric acid
"The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Ceftriaxone."
Clinical Note
moderateWarfarin + Ceftriaxone
"Warfarin may increase the anticoagulant activities of Ceftriaxone."
Clinical Note
moderatePhenprocoumon + Ceftriaxone
Terminal half-life: 5.8-8.7 hours in adults; prolonged to 12-24 hours in neonates and 30-90 hours in severe renal impairment.
Primarily renal (90–95%) as unchanged drug via glomerular filtration and tubular secretion; biliary excretion negligible (<1%)
Renal (33-67% unchanged) and biliary (up to 40%) with fecal elimination. In neonates, renal excretion is lower (~20%).
Category C
Category C
Cephalosporin Antibiotic
Cephalosporin Antibiotic
"Phenprocoumon may increase the anticoagulant activities of Ceftriaxone."